Fabian Jordan

Mr. Fabian Jordan

Universitätsspital Basel Cardiovascular Research Institute Basel, Basel, Basel-Stadt, Switzerland

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 November 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
MHMatthias Haegele
Matthias Haegele
ADAleksandar Djurdjevic
Aleksandar Djurdjevic
FJFabian Jordan
Fabian Jordan
YLYu-Ching Liu
Yu-Ching Liu
LMLeonie Mildner
Leonie Mildner
OPOtmar Pfister
Otmar Pfister
In 2019 the European Society of Cardiology (ESC) lowered the target values for low-density lipoprotein cholesterol (LDL-C) from <1.8 mmol/L to <1.4 mmol/L for secondary prevention of cardiovascular disease (CVD). The aim of this study was to determine the clinical impact of the 2019 ESC/EAS dyslipidaemia guidelines on lipid-lowering therapies and achievement rates of LDL-C targets in a contemporary cohort of CAD patients participating in an ambulatory cardiac rehabilitation (CR) program.We conducted a retrospective analysis of prospectively collected data from the Swiss Secondary Prevention Registry (SwissPR) in patients with Coronary Artery Disease (CAD), who completed the ambulatory cardiovascular rehabilitation program (CR) of the University Hospital Basel, Switzerland from January 2017 to April 2021. To evaluate the impact of the guideline publication, the cohort was split into a pre-Guideline 2019 group (A) and a post-Guideline 2019 group (B). In total 1320 patients were screened leaving 875 patients for analysis. At discharge, more patients in group B were on maximal statin doses (20% vs. 9%, p < 0.0001) and on combination therapy with ezetimibe (51% vs. 17%, p < 0.0001) than in group A, which resulted in 53% of patients reaching the LDL-C target of 50% of the LDL-C target <1.4 mmol/L in CAD patients participating in ambulatory CR.